1. Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia.
- Author
-
Plaza-Diaz, Julio, Ruiz-Ojeda, Francisco Javier, López-Plaza, Bricia, Brandimonte-Hernández, Marco, Álvarez-Mercado, Ana Isabel, Arcos-Castellanos, Lucía, Feliú-Batlle, Jaime, Hummel, Thomas, Palma-Milla, Samara, and Gil, Angel
- Subjects
THERAPEUTIC use of antineoplastic agents ,ORAL microbiology ,SALIVA analysis ,MALNUTRITION ,PLACEBOS ,RESEARCH funding ,TASTE disorders ,BLIND experiment ,STATISTICAL sampling ,LOGISTIC regression analysis ,STRAWBERRIES ,HUMAN microbiota ,RANDOMIZED controlled trials ,NUTRITIONAL status ,QUALITY of life ,MEDICINAL plants ,CANCER patient psychology ,TUMOR necrosis factors - Abstract
Simple Summary: Patients suffering from taste disorders have been unable to find treatments in the pharmaceutical industry. In this study, a novel strategy has been presented to reduce side effects in patients suffering from cancer by administering dried miracle berries (DMBs), which contain the taste-modifying glycoprotein miraculin, as an adjuvant to medical-nutritional therapy. During a three-month pilot randomized, parallel, triple-blind, and placebo-controlled clinical trial, malnourished patients with cancer and dysgeusia received either a standard dose of DMB, a high dose of DMB, or a placebo. We analyzed the oral microbiome of patients who consumed a DMB or placebo tablet before each main meal. Patients with cancer and dysgeusia who consumed DMB regularly displayed changes to their oral microbiome, which may have contributed to the maintenance of an appropriate immune response. Background/Objectives: Dysgeusia contributes to the derangement of nutritional status in patients with cancer as well as worsening the quality of life. There has been a lack of effective treatments for taste disorders provided by the pharmaceutical industry. Methods: This was a pilot randomized, parallel, triple-blind, and placebo-controlled intervention clinical trial in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment were randomized into three arms [standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry)] for three months. Patients consumed a DMB or placebo tablet before each main meal. Using the nanopore methodology, we analyzed the oral microbiome of patients with cancer using saliva samples. Results: All patients with cancer and dysgeusia had dysbiosis in terms of lower bacterial diversity and richness. DMB consumption was associated with changes in oral microbiome composition. Neither selected bacteria nor taste perception, type of diet, and cytokine levels were associated with mucositis. Likewise, alcohol and tobacco consumption as well as general and digestive toxicity due to systemic therapy were not associated with specific changes of the oral microbiome, according to logistic binary regression. The standard dose of DMB resulted in a lower abundance of Veillonella compared with the high DMB dose and placebo at 3 months after intervention with DMB. In particular, some species such as Streptococcus parasanguinis, Veillonella parvula, and Streptococcus mutans were less abundant in the DMB standard-dose group. Additionally, the consumption of a standard dose of DMB revealed a negative association between the concentrations of TNF-α and the abundance of species such as Streptococcus thermophilus, Streptococcus pneumoniae, Streptococcus dysgalactiae and Streptococcus agalactiae. Conclusions: Accordingly, regular DMB consumption could modify the oral microbiome in patients with cancer and dysgeusia, which may contribute to maintaining an appropriate immune response. However, as the present pilot study involved a small number of participants, further studies are necessary to draw robust conclusions from the data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF